7/1/2023 0 Comments Actively open linkedin 2018![]() The AI oncology diagnostics system outlines the detected tumour regions (also measuring maximum diameter for each region) and presents them to the histopathologist for making the diagnosis it also re-ranks multiple lymph node slides that belong to a single case from high to low or no tumour content for a further efficiency boost. It is the first CE-Marked metastasis detection system to identify tumours from four different cancer types: breast, lung, colon and melanoma, accounting for ~43% of total cancer incidence. DeepPath™ – LYDIA focuses on the former diagnostic aspect, namely staging, to offer decision support to histopathologists.ĭeepPath™ – LYDIA is a groundbreaking AI oncology diagnostics system that detects metastatic tumours on digitised microscope slides of Hematoxylin & Eosin (H&E) stained lymph nodes. The oncologists completely alter the consequent diagnostic procedures and therapeutic protocols if a tumour has metastasised. On the other hand, in staging, tissue sections from lymph nodes surrounding the tumour site are examined under a microscope to determine whether the tumour has spread beyond the primary site, an event known as metastasis. This indicates the tumour’s aggressiveness and guides the oncologists towards specific therapeutic strategies. ![]() In grading a tumour, a tumorous tissue section is examined under a microscope, and based on the morphological characteristics of the whole tumour and the tumour cells, the cancer type and subtype are deduced. Histopathological diagnosis in cancer consists of two main pillars: grading and staging. How does the AI oncology diagnostics system, DeepPath™ – LYDIA, work? That shortage of pathologists causes pathology departments to be under intense pressure, resulting in a 15% drop in diagnostic accuracy, long waiting times to receive results, and up to two months of treatment delays.Īll these issues directly affect patient outcomes, overall survival, and quality of life. ![]() The USA reports state a 20% decrease in active pathologists in the past decade. In 2018, 97% of pathology departments in the UK reported inadequate staffing. Secondly, the field of histopathology needs more experts.Īccording to the Royal College of Pathologists workforce survey (2018), pathology requests grow at 4.5% p.a., while staff numbers grow by only 1.2%. In addition, histopathology itself drives patient management and affects the outcome of patient treatment. Cancer incidence is growing globally as the population ages, and histopathology is at the centre of all diagnostics. ![]() The oncology-histopathology combination was selected as our initial focus for two reasons. ![]() AI oncology diagnostics can support overstretched pathologists The system was CE-Marked in May 2022 as a Class I decision support product as per IVDD. Through the support of SBRI we developed an AI-powered product, DeepPath™ – LYDIA, to assist histopathologists in performing lymph node metastasis detection quickly and accurately.ĭeepPath™ – LYDIA is expected to improve and accelerate the oncology diagnosis and treatment pipeline, which is currently under pressure. Image © XH4D | iStock DeepMed has developed an AI oncology diagnostics system, DeepPathTM – LYDIA, to assist histopathologists in performing lymph node metastasis detection quickly and accuratelyĭeepMed is an ISO-13485 certified start-up MedTech company based in Manchester, UK. ![]()
0 Comments
Leave a Reply. |